CN115380028A - 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物 - Google Patents

用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物 Download PDF

Info

Publication number
CN115380028A
CN115380028A CN202180026721.8A CN202180026721A CN115380028A CN 115380028 A CN115380028 A CN 115380028A CN 202180026721 A CN202180026721 A CN 202180026721A CN 115380028 A CN115380028 A CN 115380028A
Authority
CN
China
Prior art keywords
optionally substituted
atoms
available
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180026721.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·斯拉斯
J·阿劳约
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mindset Pharmaceutical Co ltd
Original Assignee
Mindset Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Pharmaceutical Co ltd filed Critical Mindset Pharmaceutical Co ltd
Publication of CN115380028A publication Critical patent/CN115380028A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180026721.8A 2020-02-04 2021-02-04 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物 Pending CN115380028A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969894P 2020-02-04 2020-02-04
US62/969,894 2020-02-04
PCT/CA2021/050122 WO2021155467A1 (en) 2020-02-04 2021-02-04 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
CN115380028A true CN115380028A (zh) 2022-11-22

Family

ID=77199114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180026721.8A Pending CN115380028A (zh) 2020-02-04 2021-02-04 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物

Country Status (11)

Country Link
US (3) US11453689B2 (https=)
EP (1) EP4100403A4 (https=)
JP (2) JP7824222B2 (https=)
KR (1) KR20220137085A (https=)
CN (1) CN115380028A (https=)
AU (1) AU2021215709A1 (https=)
BR (1) BR112022015379A2 (https=)
CA (1) CA3166940A1 (https=)
IL (1) IL295374A (https=)
MX (1) MX2022009528A (https=)
WO (1) WO2021155467A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
AU2022229037A1 (en) * 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
JP2024520017A (ja) * 2021-05-26 2024-05-21 マインドセット ファーマ インコーポレイテッド 幻覚剤と脂肪酸との併用
EP4347559A4 (en) * 2021-06-02 2025-04-09 Saint Joseph's University FLUORINATED TRYPTAMINE COMPOUNDS, RELATED ANALOGUES AND METHODS USING THEM
CA3229361A1 (en) * 2021-08-20 2023-02-23 Abdelmalik Slassi 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
AU2023215456A1 (en) * 2022-02-01 2024-08-01 Caamtech, Inc. Psychedelic compounds and their therapeutic uses
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
KR20250034020A (ko) * 2022-04-19 2025-03-10 마인드셋 파마 인크. 세로토닌 관련 장애를 치료하는 데 유용한 세로토닌성 제제로서의 인돌린 유도체
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
CN1121689A (zh) * 1993-04-27 1996-05-01 美国辉瑞有限公司 吲哚衍生物作为5ht1拮抗剂的应用
CN1136432A (zh) * 1992-03-05 1996-11-27 美国辉瑞有限公司 吲哚衍生物
CN1225362A (zh) * 1992-04-07 1999-08-11 美国辉瑞有限公司 吲哚衍生物
WO2007137227A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
CN107635555A (zh) * 2014-06-26 2018-01-26 康特拉医药公司 丁螺环酮代谢物的用途
CN108026073A (zh) * 2015-09-10 2018-05-11 苏文生命科学有限公司 作为毒蕈碱性m1受体正向别构调节剂的氟吲哚衍生物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
US5955462A (en) 1996-10-31 1999-09-21 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
WO2001094310A1 (en) 2000-06-07 2001-12-13 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
ES2357129T3 (es) 2005-04-13 2011-04-19 Neuraxon Inc. Compuestos indólicos sustituidos que tienen actividad inhibidora de nos.
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
JP5137849B2 (ja) 2006-01-19 2013-02-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしての置換インドリル−アルキル−アミノ−誘導体
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
US20090014868A1 (en) 2007-07-10 2009-01-15 International Business Machines Corporation Manufacturing ic chip in portions for later combining, and related structure
KR20100103799A (ko) 2007-11-16 2010-09-28 네우렉슨 인코포레이티드 내장통을 치료하기 위한 인돌 화합물 및 방법
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
WO2010132072A1 (en) 2009-05-15 2010-11-18 Neuraxon, Inc Treatment or prevention of migraine by dosing at aura
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
US20190358238A1 (en) 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CA3077053A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation Methods and compositions for inhibition of stat3
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
AU2020215150B8 (en) 2019-01-30 2025-07-03 Diamond Therapeutics Inc. Methods and compositions comprising a 5HT receptor agonist for the treatment of psychological, cognitive, behavioral, and/or mood disorders
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3160793A1 (en) 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
MX2022009528A (es) * 2020-02-04 2022-11-14 Mindset Pharma Inc Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc.
JP2023514559A (ja) 2020-02-05 2023-04-06 イエール ユニバーシティ 頭痛障害の幻覚剤処置
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN115867533B (zh) 2020-06-30 2024-07-23 加拿大瑞安神经科学公司 色胺前药
WO2022018709A1 (en) 2020-07-21 2022-01-27 Ai Pharmaceuticals Jamaica Limited Compositions and methods for treatment of psychoses and psychotic disorders
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1136432A (zh) * 1992-03-05 1996-11-27 美国辉瑞有限公司 吲哚衍生物
CN1225362A (zh) * 1992-04-07 1999-08-11 美国辉瑞有限公司 吲哚衍生物
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
CN1121689A (zh) * 1993-04-27 1996-05-01 美国辉瑞有限公司 吲哚衍生物作为5ht1拮抗剂的应用
WO2007137227A1 (en) * 2006-05-22 2007-11-29 Vanda Pharmaceuticals, Inc. Treatment for depressive disorders
CN107635555A (zh) * 2014-06-26 2018-01-26 康特拉医药公司 丁螺环酮代谢物的用途
CN108026073A (zh) * 2015-09-10 2018-05-11 苏文生命科学有限公司 作为毒蕈碱性m1受体正向别构调节剂的氟吲哚衍生物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEREK C. COLE: "Discovery of 5-Arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole Derivatives as Potent, Selective 5-HT6 Receptor Agonists and Antagonists", JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, no. 2, pages 353 - 356, XP007904922, DOI: 10.1021/jm049243i *
ERMITAS ALCALDE: "Indene-based frameworks targeting the 5-HT6 serotonin receptor: Ring constraint in indenylsulfonamides using cyclic amines and structurally abbreviated counterparts", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 17, no. 20, pages 7387 - 18 *
MADINA GERASIMOV: "Further Studies on Oxygenated Tryptamines with LSD-like Activity Incorporating a Chiral Pyrrolidine Moiety into the Side Chain", JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 20, pages 4257 - 4263, XP055943620, DOI: 10.1021/jm990325u *
RUBIO-BELTRAN: "Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan", BRITISH JOURNAL OF PHARMACOLOGY, vol. 176, no. 24, pages 4681 - 4695, XP071124237, DOI: 10.1111/bph.14832 *

Also Published As

Publication number Publication date
CA3166940A1 (en) 2021-08-12
KR20220137085A (ko) 2022-10-11
EP4100403A1 (en) 2022-12-14
US20230105399A1 (en) 2023-04-06
US20240336641A1 (en) 2024-10-10
JP2026053548A (ja) 2026-03-25
MX2022009528A (es) 2022-11-14
US11453689B2 (en) 2022-09-27
US20220017550A1 (en) 2022-01-20
BR112022015379A2 (pt) 2022-09-27
JP2023512821A (ja) 2023-03-29
WO2021155467A1 (en) 2021-08-12
IL295374A (en) 2022-10-01
US12054504B2 (en) 2024-08-06
EP4100403A4 (en) 2024-01-03
AU2021215709A1 (en) 2022-09-01
JP7824222B2 (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
JP7824222B2 (ja) 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての３－ピロリジンインドール誘導体
CN115397810A (zh) 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
US20240166630A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
JP2023553094A (ja) 中枢神経系障害の治療のためのセロトニン作動性薬としての３位環－アミンインドール誘導体
US20250034106A1 (en) 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
JP2025529948A (ja) セロトニンに関する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体
HK40083776A (en) 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40105243A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40106138A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40083780A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40084439A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40091505A (zh) 用於治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40083776

Country of ref document: HK